Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) (Radiation Oncology, (2021), 16, 1, (163), 10.1186/s13014-021-01888-1)

Catherine R. Hanna*, Sean M. O’Cathail, Janet S. Graham, Mark Saunders, Leslie Samuel, Mark Harrison, Lynsey Devlin, Joanne Edwards, Daniel R. Gaya, Caroline A. Kelly, Liz Anne Lewsley, Noori Maka, Paula Morrison, Louise Dinnett, Susan Dillon, Jacqueline Gourlay, Jonathan J. Platt, Fiona Thomson, Richard A. Adams, Campbell S.D. Roxburgh

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

After publication of this article [1], the authors reported that the Funding information section was incomplete. The following should have been added: “This work was supported by CRUK (Grant Number C61974/A2429).” The original article [1] has been updated.

Original languageEnglish
Article number230
Number of pages1
JournalRadiation Oncology
Volume16
Early online date2 Dec 2021
DOIs
Publication statusPublished - Dec 2021

Fingerprint

Dive into the research topics of 'Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) (Radiation Oncology, (2021), 16, 1, (163), 10.1186/s13014-021-01888-1)'. Together they form a unique fingerprint.

Cite this